Previous 10 | Next 10 |
In a note, UBS regards the republished results from one of the first randomized trials evaluating malaria drug hydroxychloroquine (HCQ) in COVID-19 patients as "inconclusive." More news on: Tekla World Healthcare Fund, BlackRock Health Sciences Trust, The Gabelli Healthcare & Well...
Pfizer (NYSE: PFE) swam against the current last year. Unfortunately, it was a bad time to do so. While the S&P 500 Index soared nearly 29% higher, Pfizer's shares fell 10%. So far in 2020, Pfizer isn't swimming against the current any longer. Shareholders wish it would. The stock has...
HERTFORDSHIRE, England , PITTSBURGH and MUMBAI, India , March 27, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Lupin Limited (Lupin) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinio...
The COVID-19 pandemic is affecting our social lives, as governmental authorities in most U.S. states have implemented drastic measures -- including social distancing -- to mitigate the spread of the disease. The outbreak also continues to wreak havoc on equity markets. Year to date, the S&P...
The coronavirus pandemic has so far resulted in the shutdown of economies around the globe and driven stocks into a bear market. Biotech and pharmaceutical companies are racing to develop treatments and prevention for COVID-19, the illness caused by the new coronavirus. And at the same time, a s...
Allakos Reports Encouraging Data for Antolimab Allakos (ALLK) announced that it has received positive response from Phase 1 trial of its lead drug candidate antolimab. Phase 1 trial is an open label study designed to evaluate the lead drug candidate in seven patients suffering from moder...
Pfizer 's (NYSE: PFE) plans to merge its huge post-exclusivity segment, Upjohn, with another giant drugmaker, Mylan (NASDAQ: MYL) hit a coronavirus induced snag. According to Mylan, the plan to create a new company with between $19 billion and $20 billion in combined annual revenue w...
In a note, UBS reports that India's Directorate General of Foreign Trade has instituted a moratorium on the export of hydroxychloroquine, a malaria drug in high demand for the treatment of severely ill COVID-19 patients, although the fulfillment of orders placed before the ban will be allowe...
According to a statement from US President Donald Trump, the US Food and Drug Administration (FDA) will fast-track treatments for novel coronavirus (COVID-19). Though there are still months of research ahead, there are several new developments from drug developers and producers that are giv...
Citing delays associated with the COVID-19 pandemic, Mylan N.V. (NASDAQ: MYL ) and Pfizer (NYSE: PFE ) now expect the merger between Mylan and Upjohn to be finalized in H2 instead of next quarter. More news on: Mylan N.V., Pfizer Inc., Healthcare stocks news, Merger & acquisition new...
News, Short Squeeze, Breakout and More Instantly...
Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc. PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Nov. 6, 2020 HERTFORDSHIRE, England and PITTSBURGH , Nov. 6, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ...
Our experts issued a rare "Double Down" Buy alert on this one stock... Learn more. A long-awaited deal will soon be done. Pfizer (NYSE: PFE) and Mylan (NASDAQ: MYL) announced last week that the U.S. Federal Trade Commission has approved the planned merger of Pfizer's...
Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets for Viatris PR Newswire HERTFORDSHIRE, England, and PITTSBURGH, Nov. 2, 2020 HERTFORDSHIRE , England, and PITTSBURGH, Nov. 2, 2020 /PRNews...